- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07951684
Streptococcus Salivarius Evol12® in Improving Quality of Life in Locally Advanced Head and Neck Cancer Treated With Radio(Chemo)Therapy: SMILE (SMILE)
Streptococcus Salivarius Evol12® in Improving Quality of Life In Locally Advanced Head and Neck Cancer Treated With radiochEmotherapy: SMILE, a Monocentric National Randomized Double Blind Interventional Study
The clinical study will involve the use of a dietary supplement based on the oral probiotic strain Streptococcus salivarius Evol12® in patients with head and neck cancer undergoing radiochemotherapy, with the aim of improving their quality of life. The hypothesis is that, as already outlined in scientific literature, modifying the oral microbiota through the use of the commensal S. salivarius, increasing its concentration and reducing the main pathogens in the oral cavity, may protect these patients and reduce the impact on their quality of life . A discovery of this kind would allow patients with head and neck cancer to be treated not only with standard therapy but also with treatments designed to modify the oral microbiota, which is not currently taken into consideration, in order to improve these patients' quality of life and compliance with treatment. Compared to the S. salivarius K12 strain, the S. salivarius eK12 (Evol12®) strain has a genome that is entirely similar to K12, but with a hypothetically greater antibacterial activity due to the presence of two specific genetic differences which allow for increased release of a bacteriocin: the salivabactin. Streptococcus salivarius eK12 (Evol12®) has undergone mutagenesis, acute toxicity, and subchronic toxicity studies in animals, conducted according to OECD guidelines by a GLPcertified laboratory, confirming its safety of use and absence of toxicity (In vitro and In vivo safety evaluation of Streptococcus salivarius eK12, a genetically modified dietary probiotic derived from the oral probiotic S. salivarius K12). In addition, a randomized, double-blind, placebo-controlled clinical trial conducted in healthy adults has been published, demonstrating its complete safety of use even at high dosages.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Aurora Mirabile Medical oncologist
- Puhelinnumero: +39 02 2643 3526
- Sähköposti: mirabile.aurora@hsr.it
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Participants are willing and able to give informed consent for participation in the study.
- Aged >=18 years
- Patients diagnosed with non-metastatic head and neck malignant tumors, with an Eastern Cooperative Oncology Group performance status of ≤2, planning to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
- Patient affected by squamocellular carcinoma of oral cavity, larynx, hypopharynx, oropharynx and undifferentiated or squamocellular carcinoma of nasopharynx.
- Patients eligible for to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
Exclusion Criteria:
- Patients with a history of allergy to probiotics or severe allergic constitution
- Use of antibiotics/antifungal drugs within 1 month or antimicrobial mouthwash within 1 week before the study
- Poor oral hygiene and/or severe periodontal diseases (CTCAE 5.0 Grading >/=2)
- Any previous RT to the head and neck region
- Those deemed unsuitable for the study by the investigators (concomitant with any other severe diseases)
- Allergies: history of known allergies to probiotics or to product excipients.
- Recent antimicrobial therapies: use of systemic antibiotics or antifungals within 1 month, or antimicrobial mouthwashes within 1 week.
- Oral cavity conditions: severely compromised oral hygiene or severe periodontal disease.
- Previous radiotherapy: any prior radiotherapy (RT) to the head and neck region.
- Severe comorbidities: severe concomitant diseases that make the patient unsuitable according to clinical judgment.
- Pregnancy and breastfeeding
- Contraindication related to probiotic composition
- Primary sites different from the ones described in inclusion criteria
- Patient unfit to cisplatin
- Immunocompromised Patients
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Placebo Comparator: placebo group
The placebo lozenges will be identical in appearance, taste, and composition, but will contain only excipients (sugar and starch), without any active bacteria. |
Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration |
|
Kokeellinen: group treated with probiotic: Streptococcus salivarius Evol12®
The investigational product (Bactoblis® Evol, containing the probiotic strain Streptococcus salivarius Evol12®) will be provided in the form of oral lozenges, each containing ≥ 1 × 10⁹ colony-forming units (CFU) of viable S. salivarius Evol12® cells as the active ingredient. Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. |
Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration, in order to ensure optimal mucosal contact and promote probiotic colonization. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
EORTC QLQ-H&N35 score
Aikaikkuna: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Change in quality of life assessed using the EORTC QLQ-H&N35 scale before treatment, 3 weeks, at the end of treatment (8 weeks) and thereafter for up to 8 weeks. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
days
Aikaikkuna: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Time to onset (days) of WHO grade ≥2 and ≥3. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
days
Aikaikkuna: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Duration (days) of WHO grade ≥2 and ≥3. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
Percentage
Aikaikkuna: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Rate of RT/chemotherapy interruptions, dose reduction or delay due to toxicity. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
Numeric Rating Scale (NRS)
Aikaikkuna: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Change in Pain Scores Over Time, assessed using the Numeric Rating Scale (NRS; 0-10), where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity and a worse outcome. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
Percentage
Aikaikkuna: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Percentage of patients requiring enteral or parenteral nutritional support according to the percentage of weight loss (≥5% o ≥10%). |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
days
Aikaikkuna: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
duration of RT/chemotherapy interruptions, dose reduction or delay due to toxicity. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- SMILE
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .